Skip to content
10-K

Annual Report

LIMINATUS PHARMA, INC. LIMN LIMNW

0001104659-26-037933

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 44.88M sh
Shares Diluted FY 2025 · Dec 31, 2025 23.75M sh
Shares Diluted FY 2025 · Dec 31, 2024 17.5M sh
Capex FY 2025 · Dec 31, 2025 $13.11K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$9.96M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$1.45M
Short Term Debt FY 2025 · Dec 31, 2025 $1.44M
Short Term Debt FY 2025 · Dec 31, 2024 $19.97M
Stockholders Equity FY 2025 · Dec 31, 2025 −$9.81M
Stockholders Equity FY 2025 · Dec 31, 2024 −$19.34M
Stockholders Equity FY 2025 · Dec 31, 2023 −$15.79M
Current Liabilities FY 2025 · Dec 31, 2025 $10.3M
Current Liabilities FY 2025 · Dec 31, 2024 $24.75M
Total Liabilities FY 2025 · Dec 31, 2025 $10.33M
Total Liabilities FY 2025 · Dec 31, 2024 $24.75M
Current Assets FY 2025 · Dec 31, 2025 $500.57K
Current Assets FY 2025 · Dec 31, 2024 $5.28M
Total Assets FY 2025 · Dec 31, 2025 $512.8K
Total Assets FY 2025 · Dec 31, 2024 $5.41M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.43
Eps Diluted FY 2025 · Dec 31, 2024 −$0.20
Eps Basic FY 2025 · Dec 31, 2025 −$0.43
Eps Basic FY 2025 · Dec 31, 2024 −$0.20
Sga Expense FY 2025 · Dec 31, 2025 $2.97M
Sga Expense FY 2025 · Dec 31, 2024 $644.62K
Net Income FY 2025 · Dec 31, 2025 −$10.21M
Net Income FY 2025 · Dec 31, 2024 −$3.55M
Operating Income FY 2025 · Dec 31, 2025 −$2.97M
Operating Income FY 2025 · Dec 31, 2024 −$3.33M
Rd Expense FY 2025 · Dec 31, 2024 $2.69M